A cross-sectional analysis shows that long-acting antiretroviral therapy sustains viral suppression regardless of initial ...

Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case ... for testing and nPEP regimens for persons exposed who have ...

Updated recommendations for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published in the ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based ...

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based ...

Metformin use in patients with HIV and type 2 diabetes who had at least 2 years of exposure to effective ART showed no significant effect on immune reconstitution.

Women living with HIV have been dropped as a priority population for testing in the latest HIV strategy, despite being more likely to be diagnosed late. Researchers say women with HIV face unique ...

Now, researchers from UVA Health have uncovered a promising link between drugs initially developed for HIV and reduced Alzheimer's risk, highlighting an unexpected pathway for potential prevention.

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 ...

May 5, 2025 — People living with HIV are less likely to receive potentially lifesaving cancer treatment if they live in communities with lower income levels and educational attainment ...